RHYTHM PHARMACEUTICALS, INC.

RYTM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015
Revenue $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $50.3M $22.9M $19.6M $7.1M
SG&A Expense $28.1M $9.5M $6.3M $3.4M
Operating Income $-78.4M $-32.4M $-25.9M $-10.6M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-74.1M $-33.7M $-25.9M $-11.1M
Net Margin
EPS (Basic) $-2.39 $-2.83 $-2.85 $-1.18
EPS (Diluted) $-2.39 $-2.83 $-2.85 $-1.18
Shares Outstanding (Basic) 34.4M 27.3M 10.2M
Shares Outstanding (Diluted) 34.4M 27.3M 10.2M
Dividends Per Share
← Newer Page 2 of 2 Older →